Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen.

Authors: Mueller NH,Pattabiraman N,Ansarah-Sobrinho C,Viswanathan P,Pierson TC,Padmanabhan R,
Address: Department of Microbiology and Immunology, Georgetown University School of Medicine, Washington, DC 20057, USA.
Journal: Antimicrob Agents Chemother.


Publication: 2008 Sep;52(9):3385-93. doi: 10.1128/AAC.01508-07. Epub 2008 Jul 7.
Free Text: Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen.

abstract

west nile virus and dengue virus are mosquito-borne flaviviruses that cause a large number of human infections each year. No vaccines or chemotherapeutics are currently available. These viruses encode a serine protease that is essential for polyprotein processing, a required step in the viral replication cycle. In this study, a high-throughput screening assay for the West Nile virus protease was employed to screen approximately 32,000 small-molecule compounds for Identification of inhibitors. Lead inhibitor compounds with three distinct core chemical structures (1 to 3) were identified. In a secondary screening of selected compounds, two compounds, belonging to the 8-hydroxyquinoline family (compounds A and B) and containing core structure 1, were identified as potent inhibitors of the West Nile virus protease, with K(i) values of 3.2 +/- 0.3 microM and 3.4 +/- 0.6 microM, respectively. These compounds inhibited the dengue virus type 2 protease with K(i) values of 28.6 +/- 5.1 microM and 30.2 +/- 8.6 microM, respectively, showing some selectivity in the inhibition of these viral proteases. However, the compounds show no inhibition of cellular serine proteases, trypsin, or factor Xa. Kinetic analysis and molecular docking of compound B onto the known crystal structure of the West Nile virus protease indicate that the inhibitor binds in the substrate-binding cleft. Furthermore, compound B was capable of inhibiting West Nile virus RNA replication in cultured Vero cells (50% effective concentration, 1.4 +/- 0.4 microM; selectivity index, 100), presumably by inhibition of polyprotein processing.



Related Articles
Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
Antivir Chem Chemother. 2011
Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
Cregar-Hernandez L, Jiao GS, Johnson AT, Lehrer AT, Wong TA, Margosiak SA. Antivir Chem Chemother. 2011 May 12; 21(5):209-17. Epub 2011 May 12.
Characterization of the West Nile virus protease substrate specificity and inhibitors.
Int J Biochem Cell Biol. 2007
Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH, Yon C, Ganesh VK, Padmanabhan R. Int J Biochem Cell Biol. 2007; 39(3):606-14. Epub 2006 Nov 23.
Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.
Bioorg Med Chem Lett. 2009
Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.
Sidique S, Shiryaev SA, Ratnikov BI, Herath A, Su Y, Strongin AY, Cosford ND. Bioorg Med Chem Lett. 2009 Oct 1; 19(19):5773-7. Epub 2009 Aug 3.
Review West Nile Virus NS2B/NS3 protease as an antiviral target.
Curr Med Chem. 2008
Review West Nile Virus NS2B/NS3 protease as an antiviral target.
Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. Curr Med Chem. 2008; 15(27):2771-84.
Review Structure-based discovery of dengue virus protease inhibitors.
Antiviral Res. 2009
Review Structure-based discovery of dengue virus protease inhibitors.
Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. Antiviral Res. 2009 Jun; 82(3):110-4. Epub 2009 Feb 21.
In silico modeling of ligand molecule for non structural 3 (NS3) protein target of flaviviruses.
Bioinformation. 2012
In silico modeling of ligand molecule for non structural 3 (NS3) protein target of flaviviruses.
Agnihotri S, Narula R, Joshi K, Rana S, Singh M. Bioinformation. 2012; 8(3):123-7. Epub 2012 Feb 3.
An investigation of phenylthiazole antiflaviviral agents.
Bioorg Med Chem. 2011
An investigation of phenylthiazole antiflaviviral agents.
Mayhoub AS, Khaliq M, Botting C, Li Z, Kuhn RJ, Cushman M. Bioorg Med Chem. 2011 Jun 15; 19(12):3845-54. Epub 2011 May 3.
Structure based drug designing of a novel antiflaviviral inhibitor for nonstructural 3 protein.
Bioinformation. 2011
Structure based drug designing of a novel antiflaviviral inhibitor for nonstructural 3 protein.
Jitendra S, Vinay R. Bioinformation. 2011 Mar 26; 6(2):57-60. Epub 2011 Mar 26.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.